Dr. Hytham Al-Masri
President & CEO
Renee Porras
Vice President of Global Operations
Mahdy Amine
SVP, General Counsel
Bridgette Bonilla
Vice President of Quality Assurance
Michael Salerno
Director of Operations
Victoria Shusharina
Senior Hematopathologist, Director of Flow Cytometry
Hikmat Daghestani
Senior Scientific Director
Shuntae Williams
Scientific & Regulatory Affairs Director
Kimberly Smith
Scientific Director
Renata Budz
Senior Manager, Operations
Mahreen Suleman
Operations Manager, UK
2007 Hematogenix® is founded in Chicago, USA by Dr. Hytham Al-Masri with only two employees and a leased space of 2,000 sq. ft.
2008 Hematogenix launches Flow Cytometry and Molecular Departments, receives and reports first patient sample, and is awarded CAP accreditation & CLIA certification.
2009 Hematogenix expands its workspace to 6,000 sq. ft., adds 20 full-time employees, and launches Cytogenetics Department.
2010 Hematogenix doubles its workforce, launches Histology Department, and Diagnostic Services expand to reach the entire United States.
2012 Hematogenix designs and constructs a dynamic facility spanning 32,000 sq. ft. and launches Pharma Services division, R&D, and Biomarker Services.
2014 Hematogenix expands internationally into Manchester, UK with Pharma Services extending to sponsors globally across multiple platforms and technologies.
2016 Hematogenix receives CAP accreditation in Manchester, UK, employing over 100 professionals worldwide.
2017 Hematogenix® is recognized as a global leader in immuno-oncology and PD-L1 testing, and launches Next-Generation Sequencing (NGS).
2018 Hematogenix celebrates its 10th anniversary, with nearly 200 employees worldwide, and introduces an enhanced Digital Pathology solution.
2019 Hematogenix expands into Kuala Lumpur, Malaysia and Shanghai, China.
2020 Hematogenix expands its services to include measurable/minimal residual disease (MRD) for Chronic Lymphocytic Leukemia (CLL) monitoring.